Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on November 24, 2008

Circulation. 2008
Published online before print November 24, 2008, doi: 10.1161/CIRCULATIONAHA.108.792986
A more recent version of this article appeared on December 9, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
118/24/2533    most recent
CIRCULATIONAHA.108.792986v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frankel, D. S.
Right arrow Articles by Tofler, G. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frankel, D. S.
Right arrow Articles by Tofler, G. H.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Diabetes
*Genetics Home Reference
Related Collections
Right arrow Risk Factors
Right arrow Arterial thrombosis
Right arrow Aggregation
Right arrow Type 2 diabetes
Right arrow Epidemiology
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Mechanism of atherosclerosis/growth factors
Right arrowRelated Article

Submitted on May 18, 2008
Accepted on September 30, 2008

Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular Disease. The Framingham Offspring Study

David S. Frankel MD, James B. Meigs MD, MPH*, Joseph M. Massaro PhD, Peter W.F. Wilson MD, Christopher J. O'Donnell MD, MPH, Ralph B. D'Agostino PhD, and Geoffrey H. Tofler MD

From the Division of Cardiovascular Medicine (D.S.F.), Department of Medicine, University of Pennsylvania, Philadelphia, Pa; the General Medicine Division (J.B.M.) and the Cardiology Division (C.J.O.), Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston; the National Heart, Lung, and Blood Institute's Framingham Heart Study (J.M.M., C.J.O., R.B.D), Framingham, Mass; the Division of Cardiology (P.W.F.W.), Department of Medicine, Emory University School of Medicine, Atlanta, Ga; the Department of Biostatistics (J.M.M., R.B.D.), Boston University, Boston, Mass; and the Royal North Shore Hospital (G.H.T.), Sydney, Australia.

* To whom correspondence should be addressed. E-mail: jmeigs{at}partners.org.

Background—Von Willebrand factor (vWF) is inconsistently associated with cardiovascular disease (CVD). This might be explained by associations of vWF with type 2 diabetes mellitus and insulin resistance.

Methods and Results—We tested whether vWF predicted incident CVD in 3799 Framingham Offspring Study participants, and in particular, among those with type 2 diabetes mellitus or insulin resistance. During 11 years of follow-up, 351 participants developed CVD. In proportional hazards models (with adjustment for age, sex, blood pressure, smoking, body mass index, total and high-density lipoprotein cholesterol, and treatment with aspirin, insulin, antihypertensives, and lipid-lowering medications) with the lowest quartile of the vWF distribution as the referent, the hazard ratio (HR) for CVD was 0.94 in the second quartile, 0.98 in the third, and 1.32 in the highest (P=0.04 for trend). Additional adjustment for type 2 diabetes mellitus or insulin resistance (homeostasis model) partially attenuated the association (multivariable HRs for top quartile 1.28 and 1.21, respectively). We then stratified the models by diabetes status or the homeostasis model of insulin resistance distribution (top quartile versus lower 3 quartiles). vWF was associated with CVD among participants with diabetes mellitus (HR for top quartile relative to bottom 1.47, P=0.04 for trend) but not among nondiabetic participants (HR 1.15, P=0.5) and similarly among insulin-resistant (HR 1.50, P=0.01) but not insulin-sensitive (HR 1.02, P=0.9) participants.

Conclusions—Higher levels of vWF were associated with risk of CVD in people with type 2 diabetes mellitus or insulin resistance, which suggests that vWF may be a risk factor unique to these populations.


Key words: von Willebrand factor • diabetes mellitus • insulin resistance • cardiovascular diseases • epidemiology


Related Article:

Clinical Summaries
Circulation 2008 118: 2485-2487. [Extract] [Full Text]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
D. Voora, S. H. Shah, I. Spasojevic, S. Ali, C. R. Reed, B. A. Salisbury, and G. S. Ginsburg
The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
J. Am. Coll. Cardiol., October 20, 2009; 54(17): 1609 - 1616.
[Abstract] [Full Text] [PDF]